share_log

Expert Ratings For United Therapeutics

Expert Ratings For United Therapeutics

聯合療法的專家評級
Benzinga ·  05/22 01:00
During the last three months, 7 analysts shared their evaluations of United Therapeutics (NASDAQ:UTHR), revealing diverse outlooks from bullish to bearish.
在過去的三個月中,7位分析師分享了他們對聯合療法(納斯達克股票代碼:UTHR)的評估,揭示了從看漲到看跌的不同前景。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級,簡要介紹了過去30天中不斷變化的情緒,並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $310.43, with a high estimate of $400.00 and a low estimate of $240.00. This current average has increased by 5.05% from the previous average price target of $295.50.
分析師對12個月目標股價的評估提供了更多見解,顯示平均目標價爲310.43美元,最高估計爲400.00美元,低估值爲240.00美元。目前的平均價格較之前的平均目標價295.50美元上漲了5.05%。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級:詳細審查
The perception of United Therapeutics by financial experts is analyzed...
通過分析師最近的行動...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論